ClinicalTrials.gg
CompletedNCT04050163MiSaver®Updated Mar 29, 2024

MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction)

A Phase 1/2 interventional study of MiSaver® in Myocardial Infarction, sponsored by Honya Medical Inc. Completed at 2 sites in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-29.

Sponsored by Honya Medical Inc · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Myocardial Infarction with a site in Taiwan — 8 open to participants now, 10 under way, 4 of them phase 3. Myocardial Infarction · Taiwan.

Enrollment
26th of 27
11 · median 3,110
Started
2021
with 3 others
Phase 1/2
Only one
of the 35
Registered
18th of 35
by date
Lead sponsor
2 of 35
Honya Medical Inc

Among the 35 studies in Myocardial Infarction with a site in Taiwan, this one is the 26th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2021, is the only one in phase 1/2, and was the 18th registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

8 of the 35 studies in Myocardial Infarction with a site in Taiwan are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Myocardial Infarction with a site in Taiwan, or all of them as a file.
02

Study summary

The objective of the present study is to establish the safety and efficacy of MiSaver® Stem Cell Treatment After a Heart Attack (Acute Myocardial Infarction)

03

Conditions studied

  • Myocardial Infarction

Keywords

  • Heart Attack
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 20\~80
  • Acute Myocardial Infarction 1 to 10 days
  • Cardiac enzyme CK-MB or Troponin > 2X of high-end normal value
  • ST-elevation on (STEMI)
  • Presence of regional wall motion abnormality
  • (LVEF) of ≤40%
  • Hemodynamically stable past 24 hour
  • Participants with adequate pulmonary function
  • Peripheral artery oxygen saturation ≥97%
  • performance status scores of ≥60.

Exclusion criteria

Exclusion Criteria:

  • Age \<20 or >80
  • Pregnant or breast feeding
  • Positive adventitious infections (such as , hepatitis )
  • Revascularization via coronary artery bypass surgery is required
  • Coronary revascularization procedures is anticipated during the 6-month study period
  • Severe aortic or mitral valve narrowing
  • Evidence of life-threatening arrhythmia on baseline (ECG)
  • Short of breath unable to receive PCI examination or treatment
  • Malignant tumor
  • Hematopoietic dysplasia
  • Severe organ disease
  • With less than 1 year of
  • Chronic kidney disease with CCr\<20ml/min
  • Kidney disease on renal dialysis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Low Dose

    Cells dosage, 0.5x10\^7 cells/kg body weight

    Biological: MiSaver®

  • Experimental
    Intermediate Dose (aka Effective or High)

    Cells dosage, 1.6x10\^7 cells/kg body weight

    Biological: MiSaver®

  • Experimental
    Toxic Dose

    Cells dosage, 5.0 x10\^7 cells/kg body weight

    Biological: MiSaver®

Interventions

  • BiologicalMiSaver®

    Intravenous administration of MiSaver® Stem Cell via peripheral vein access.

    Also known as: stem cells

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events

    Number of Adverse Events

    Time frame: 12 months

Secondary outcomes

  1. Left ventricle stroke volume

    Echocardiogram assessment on left ventricle stroke volume (volume of blood pumped from the left ventricle per beat (ml).

    Time frame: 12 months

  2. End diastolic volume

    Echocardiogram assessment on volume of blood in the left ventricle at the end of diastolic filling (cc)

    Time frame: 12 months

  3. Left ventricular ejection fraction (LVEF)

    Calculated by dividing the volume of blood pumped from the left ventricle per beat (stroke volume) by the volume of blood collected in the left ventricle at the end of diastolic filling (end-diastolic volume).

    Time frame: 12 months

  4. Participants Functional Activity by NYHA Classification

    The New York Heart Association (NYHA) Functional Classification is a useful tool for classifying the extent of functional limitations in patients with heart conditions. The system categorizes patients into one of four categories based on the level of limitation they experience during physical activity, with symptoms ranging from mild shortness of breath or angina to more severe breathing difficulties. The NYHA classification focuses specifically on limitations related to physical activity and provides a straightforward approach to assessing a patient's condition. By using this system, healthcare providers can quickly and easily determine the level of functional limitation in their patients and tailor treatment plans accordingly.

    Time frame: 12 months

  5. Participants Functional Activity by CCS Classification

    The Canadian Cardiovascular Society grading of angina pectoris, also known as the CCS Functional Classification, is a widely used clinical tool that classifies the severity of exertional angina. It allows doctors to assess the degree of angina severity in patients, and subsequently develop a tailored treatment plan. Although there are no definitive therapy guidelines specific to each class, healthcare providers can use the CCS grading system as a framework to guide treatment planning based on the severity of angina and other individual factors such as age and the risk of major cardiac complications. By utilizing the CCS grading system, healthcare providers can ensure that patients receive personalized treatment that addresses their unique needs and circumstances.

    Time frame: 12 months

07

Study locations

2 sites
  • Chung Shan Medical University Hospital
    Taichung, Taichung City 402, Taiwan
  • HONYA Medical Inc
    Tainan, 74147, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in May 2023, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2019
First posted
Aug 8, 2019
StartActual
Jan 26, 2021
Primary completionActual
May 4, 2023
CompletionActual
May 4, 2023
Last update
Mar 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04050163
Lead sponsor
Honya Medical Inc
Responsible party
Sponsor
First posted
Aug 8, 2019
Start date
Jan 26, 2021
Primary completion
May 4, 2023
Completion
May 4, 2023
Last update
Mar 29, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem Cell

Start the discussion